AUG 5·SEC EDGARLow
FROST PHILLIP MD ET AL purchased $71K of COCP (indirect holdings)
FROST PHILLIP MD ET AL purchased 75,000 indirectly-held shares of Cocrystal Pharma, Inc. (COCP) at $0.94 on 2026-08-03.
StockNASDAQ · US · USDHealthcare · Biotechnology
$COCP
Cocrystal Pharma, Inc.
Price · $COCPvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- $80K 2 txs
- Sells
- — 0 txs
FROST PHILLIP MD ET AL2× · $80K
10b5-1 plan0%
Top stories · $COCPMore →
AUG 3·SEC EDGAR 8-K
Cocrystal Pharma, Inc. (COCP): Entry into a Material Definitive Agreement
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “ Agreement ”) entered into as of this ____ day of July, 2026 (the “ Effective Date ”) by and between OPKO Health, Inc., a Delaware corporation (the “ Purchaser ”), and
JUL 17·SEC EDGAR 8-K
Cocrystal Pharma, Inc. (COCP): Submission of Matters to a Vote of Security Holders
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001412486 0001412486 2026-07-14 2026-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
COCP sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning COCP (Cocrystal Pharma, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent COCP coverage spans financial news, corporate actions and insider activity.
In the last 30 days, COCP insiders filed 2 SEC Form 4 transactions — 2 purchases ($80K) and no sales. The most active reporter was FROST PHILLIP MD ET AL with 2 filings.
What's driving COCP
The filing signals insider buying, but the disclosed size is modest and not tied to a 10b5-1 plan, limiting near-term fundamental impact.
This is a capital-raise style equity issuance framework, with deal mechanics tied to Nasdaq bid pricing and transfer-agent delivery.
The 8-K discloses finalized shareholder votes, but it does not change business strategy or provide new financial/clinical information.
CEO transition plus detailed equity compensation can shift investor expectations for strategy and near-term execution risk.
Cocrystal Pharma's recent registered direct offering indicates a strategic effort to raise capital, which could support future clinical development or operational needs. The offering's size and structure suggest a moderate positive outlook, but potential dilution should be considered.
alphai scores every news story that mentions COCP with an AI model for sentiment and relevance, and aggregates insider trades from Cocrystal Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $COCP
Score
FROST PHILLIP MD ET AL purchased $71K of COCP (indirect holdings)
FROST PHILLIP MD ET AL purchased 75,000 indirectly-held shares of Cocrystal Pharma, Inc. (COCP) at $0.94 on 2026-08-03.
2 min readCocrystal Pharma, Inc. (COCP): Entry into a Material Definitive Agreement
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “ Agreement ”) entered into as of this ____ day of July, 2026 (the “ Effective Date ”) by and between OPKO Health, Inc., a Delaware corporation (the “ Purchaser ”), and
2 min readCocrystal Pharma, Inc. (COCP): Submission of Matters to a Vote of Security Holders
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001412486 0001412486 2026-07-14 2026-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readCocrystal Pharma, Inc. (COCP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001412486 0001412486 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
3 min readCocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants ...
3 min read
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Cocrystal Pharma (NASDAQ:COCP)
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants
3 min readCocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants ...
3 min readCocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
BOTHELL, Wash., Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- Cocrystal Pharma, Inc. ( Nasdaq: COCP ) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company's lead pan-viral protease inhibitor CDI-988 during a podium presentation at the ...
3 min readCocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Cocrystal Pharma, Inc. ( Nasdaq: COCP ) ( "Cocrystal" or the "Company" ) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 ...
2 min readCocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
BOTHELL, Wash., April 24, 2025 ( GLOBE NEWSWIRE ) -- Cocrystal Pharma, Inc. ( Nasdaq: COCP ) ( "Cocrystal" or the "Company" ) announces that its investigative drug candidate CDI-988 was shown to bind to the highly conserved region of the GII.17 protease with excellent potency, similar to that ...
3 min read